Dedicating mid-stage drug trial results to its late chief medical officer, Threshold Pharmaceuticals Inc. said Tuesday its experimental treatment for deadly pancreatic cancer passed a significant test.
The South San Francisco company (NASDAQ: THLD) said Tuesday that patients with advanced pancreatic cancer who received a combination of TH-302 and gemcitabine in the Phase IIb trial lived 5.6 months — two months longer than those who got gemcitabine alone.
Threshold stock soared nearly 74 percent by mid-day trading, up $2.61 to $6.14 per share.
No comments:
Post a Comment